PARTNERSHIP OPPORTUNITIES
Free Shipping in the U.S. for orders over $1000. Shop Now>>
28 November, 2023 by Anshul (neobio)
Welcome to our detailed guide on the CA 19-9 antibody. If you’re a research scientist like ourselves at NeoBiotechnologies, you probably understand the importance of reliable, specific monoclonal antibodies in your work. The better understanding you have of these antibodies, the stronger your research foundation becomes. The CA 19-9 antibody, is one such significant biomarker, particularly common in the world of cancer research. So let’s delve right into it!
CA 19-9, a sialylated lacto-N-fucopentose II, acts as a tumor marker in our body. This makes it incredibly crucial for research in various cancer types, including pancreatic, stomach, breast, colon, gall bladder, and ovarian carcinomas. High expression of this antibody has been identified as a potential predictor of increased cancer mortality, providing valuable insight into the direction and intensity of the disease.
What’s more important? Even though the use of CA 19-9 is widespread in cancer research, it isn’t the only application area. In some cases, higher levels of CA 19-9 can pin-point towards non-cancerous conditions like liver cirrhosis and gallstones. This dynamic nature of CA 19-9 antibody makes it an indispensable tool for research and clinical diagnostics.
Quick facts about CA 19-9 Antibody:
– Acts as a marker for different types of cancer.
– Related to the Lewis blood group.
– Can be used to monitor cancer progression and effectiveness of cancer treatment.
– Not exclusive to cancer – high levels can also indicate non-cancerous conditions.
– Not all individuals with cancer produce CA 19-9; hence, it’s not a standalone diagnostic test.
The CA 19-9 antibody has a significant role in cancer detection, particularly in monitoring pancreatic and colon cancer. But, like any scientific tool, understanding its function, benefits, and limitations is crucial for its effective use.
The CA 19-9 antibody is designed to bind to the CA 19-9 antigen, a specific carbohydrate structure often found in higher levels in cancerous tissues. In fact, it’s currently the top individual marker for pancreatic cancer detection. This protein is synthesized by glycosyltransferases, which sequentially link the monosaccharide precursors onto both N-linked and O-linked glycans.
However, the CA 19-9 antigen is not exclusively found in cancer patients. It can also rise in non-cancerous conditions like liver diseases and pancreatitis. Therefore, while it can indicate the presence of cancer, it’s not a standalone diagnostic test and is often used in conjunction with other clinical factors.
The CA 19-9 antibody is particularly effective in detecting pancreatic cancer. It’s the only FDA-approved test for this form of cancer, making it a critical tool in cancer management.
In pancreatic cancer patients, the CA 19-9 antigen is elevated in the majority of cases. However, its performance isn’t perfect due to false negatives and positives. For instance, some pancreatic cancer patients do not show an elevation in this antigen, which reduces its usefulness for confirming cancer in suspect cases.
At NeoBiotechnologies, we’re continually working on the production and validation of highly specific monoclonal antibodies, including the CA 19-9 antibody, to improve cancer detection.
When it comes to colon cancer, research has shown that the CA 19-9 antigen can also be elevated. Therefore, the CA 19-9 antibody can also indicate the presence of this type of cancer.
However, just as with pancreatic cancer, it’s essential to use this tool in conjunction with other diagnostic tests and clinical factors. Elevated levels can also be a sign of non-cancerous conditions.
At NeoBiotechnologies, our mission is to provide reliable antibodies that can significantly contribute to the detection and monitoring of various types of cancer, including colon cancer. With four decades of experience in the biotech industry, we’re committed to supporting the vital work of cancer researchers all over the world.
The CA 19-9 blood test is a simple procedure carried out by a healthcare professional. A small needle is used to collect a blood sample from a vein in your arm. After the needle is inserted, a small amount of blood is collected into a test tube or vial. The whole process typically takes less than five minutes. While you might feel a slight sting when the needle goes in or out, the discomfort is minimal and short-lived. There’s no need for any special preparations prior to the test, but it’s always a good idea to check with your healthcare provider to be sure.
Interpreting the results of the CA 19-9 blood test is not straightforward. This is because, while high levels of CA 19-9 are often a sign of pancreatic cancer, they can also indicate other types of cancer or non-cancerous conditions such as gallstones and cirrhosis of the liver. For this reason, the CA 19-9 test isn’t used alone for cancer screening or diagnosis. Instead, it’s used as a tool for monitoring cancer and assessing the effectiveness of treatment. Generally, increasing levels of CA 19-9 may suggest that the cancer is growing, while decreasing levels could mean that treatment is working and the tumor is shrinking.
One of the challenges in using CA 19-9 as a tumor marker is that different assays may yield different results. Thus, it’s crucial to use a consistent assay method when monitoring CA 19-9 levels over time. Any change in the test method could potentially lead to incomparable results, making it difficult to accurately track the progress of cancer or the effectiveness of treatment.
At NeoBiotechnologies, we understand the critical role that reliable and consistent lab testing plays in cancer research and treatment. That’s why we are committed to producing highly validated, monospecific Rabbit Recombinant Monoclonal Antibodies, including the CA 19-9 antibody, that meet the stringent requirements of the world’s top institutions and researchers. Our team of scientists rigorously validates each antibody, ensuring that they deliver precise and consistent results every time.
While the CA 19-9 antibody is primarily recognized for its role as a tumor marker, notably in pancreatic cancer, it’s vital to understand that elevated levels of this antigen can also occur in non-cancerous conditions. These include pancreatitis, liver disease, cystic fibrosis, and other digestive disorders.
Our bodies are complex systems, and sometimes, they can send confusing signals. Pancreatitis, which is inflammation of the pancreas, can lead to elevated CA 19-9 levels. Though these levels aren’t as high as those seen in pancreatic cancer, they can still cause concern.
Other digestive disorders can also affect CA 19-9 levels. Conditions like benign hepatic and biliary diseases, which are known for causing benign cholestasis and obstructive jaundice, are known to cause mild elevations in serum CA 19-9. But it’s important to remember that these increases are typically not as significant as those seen in cancer patients.
Liver diseases, such as hepatitis, liver fibrosis, and liver cysts, can also cause an increase in CA 19-9 levels. This is why it’s important to interpret elevated CA 19-9 levels with caution in patients with hepatic disease.
Cystic fibrosis, a genetic disorder that affects the lungs and digestive system, can also cause an elevation in CA 19-9 levels. Again, these levels are typically not as high as those observed in cancer cases, but they can still cause alarm if not properly contextualized.
In conclusion, while elevated CA 19-9 levels can indicate the presence of certain cancers, it’s critical to remember that they can also be associated with a variety of non-cancerous conditions. As researchers and developers of antibodies, including the CA 19-9 antibody, we at NeoBiotechnologies understand the complexity of these interactions and work tirelessly to provide the most accurate and reliable antibodies for both research and clinical use.
Understanding survival rates in cancer patients involves a complex array of factors. Among these, the CA 19-9 antibody plays a critical role. It’s not just about diagnosing cancer but also about predicting the treatment outcome. Let’s break it down.
Research suggests a link between CA 19-9 levels and survival rates in cancer patients. Specifically, the survival time for patients with a CA 19-9 level less than or equal to 90 was around 23 months. However, for those with a CA 19-9 level higher than 90, the median survival reduced to 10.4 months.
In addition, a three-year survival rate was reported to be 32% for patients with a CA 19-9 level less than or equal to 90. This figure dropped to a mere 2% for patients with CA 19-9 levels higher than 90. This data suggests that the higher the CA 19-9 level, the lower the survival rate, hinting at its potential as a prognostic marker.
High CA 19-9 levels can also affect how well a patient responds to treatment. For instance, CA 19-9-targeted human antibodies have shown potential in reducing the progression of metastatic pancreatic ductal adenocarcinoma (PDAC) in animal models.
In human studies, a cytotoxic human IgG1 antibody targeting CA 19-9 showed promising results. It not only decreased serum CA 19-9 but also prevented tumor progression in metastatic PDAC patients. This antibody, MVT-5873, is currently under investigation in phase II trials to assess its ability to eliminate micrometastases, particularly in the immediate perioperative period.
If successful, antibodies targeting CA 19-9 could become powerful tools in our fight against cancer. They could help prolong recurrence-free survival (RFS) and overall survival (OS) in patients undergoing resections for PDAC, CCA, or metastatic colorectal cancer (mCRC) to the liver.
As a leading provider of highly validated, monospecific Rabbit Recombinant Monoclonal Antibodies, we at NeoBiotechnologies are committed to supporting researchers in their quest to understand and combat cancer. We understand the potential of the CA 19-9 antibody in cancer survival prediction and are dedicated to providing reliable and accurate antibodies for research and clinical use.
In the next section, we will delve into the significance of elevated CA 19-9 levels in non-cancerous conditions and explore further applications of the CA 19-9 antibody in research and development.
After exploring the significance of elevated CA 19-9 levels in various health conditions, let’s delve into the world of research and development, where the CA 19-9 antibody is a valuable asset. Here at NeoBiotechnologies, we’re passionate about advancing scientific understanding and providing tools to facilitate robust, precise, and reliable research.
Producing high-quality antibodies that researchers can trust is a complex process, and it’s one that we take very seriously. We’re proud to manufacture over 500 highly validated, monospecific Rabbit Recombinant Monoclonal Antibodies, including the CA 19-9 antibody.
Our team of scientists painstakingly develops, manufactures, and rigorously validates each one of our antibodies. This process ensures that they are monospecific and reliable for various applications, such as Immunohistochemistry, Flow Cytometry, Western Blotting, and Immunofluorescence.
Our CA 19-9 antibody is no exception. It’s designed to bind specifically to the CA 19-9 antigen, a carbohydrate antigenic determinant that’s associated with several types of cancer. This specificity makes it an invaluable tool for researchers studying cancer pathologies.
Our CA 19-9 antibody is particularly useful in cancer research. It has been shown to label adenocarcinomas of the pancreas, stomach, breast, colon, and gall bladder. This means that it can be used to detect and study these types of cancer, helping researchers to understand their progression and develop new treatments.
For example, in gastric and breast cancer research, the CA 19-9 antibody can be used to identify tumor cells and study their behavior. The presence of the CA 19-9 antigen in these cells may indicate a more aggressive tumor, which could influence the choice of treatment.
Furthermore, the CA 19-9 antibody is also expressed in primary and metastatic ovarian carcinomas. This makes it a potentially valuable tool in the study of ovarian cancer as well.
As we continue to enhance our understanding of cancer and its various forms, tools like the CA 19-9 antibody become increasingly important. They enable us to delve deeper into the molecular mechanisms that drive cancer, providing the foundation for the development of new and more effective treatments.
From cancer detection to its role in research and development, the CA 19-9 antibody is a versatile and valuable tool. It allows us to better understand the complex nature of cancer, predict patient outcomes, and guide the development of future treatments.
Here at NeoBiotechnologies, we’re committed to providing high-quality, reliable antibodies for research and clinical use. We understand the critical role these tools play in advancing scientific knowledge and improving patient outcomes. Together, let’s continue pushing the boundaries of what’s possible in cancer research and treatment.
The journey we’ve taken through the world of CA 19-9 antibodies has hopefully underscored the paramount importance of these biomarkers in cancer management. They hold a pivotal role in the detection, monitoring, and outcome prediction of cancers, particularly pancreatic and colon cancer. However, as we’ve seen, their utility extends beyond the realm of cancer and into other health conditions such as pancreatitis, liver disease, and cystic fibrosis.
CA 19-9 antibody testing is not just a standalone test, but rather a piece of a larger diagnostic and monitoring puzzle. It helps provide a more comprehensive picture of a patient’s health status when interpreted alongside other clinical factors. A CA 19-9 blood test can offer valuable insights, but the test results need to be interpreted with care. Variations in lab testing procedures and the presence of non-cancerous conditions that can elevate CA 19-9 levels are factors that need to be taken into account.
As we’ve seen from the research, different CA 19-9 antibodies can have different binding specificities, affecting the performance of the biomarker. This underscores the importance of using high-quality, validated antibodies in research and clinical applications. This is where we at NeoBiotechnologies come in. We manufacture over 500 highly validated, monospecific Rabbit Recombinant Monoclonal Antibodies, including those for CA 19-9, which are trusted by top institutions and researchers worldwide.
Our commitment is not just to provide reliable antibodies but also to contribute to the advancement of science and improve patient outcomes. We believe in the potential of CA 19-9 antibodies, not just as a tool for today, but as a pathway to the development of future treatments. Together, let’s continue pushing the boundaries of what’s possible in cancer research and treatment.
In conclusion, while CA 19-9 antibody testing has its limitations, it remains a vital tool in our arsenal against cancer. With ongoing research and advancements in technology, the potential for improving the specificity and sensitivity of these tests is promising. As the understanding of the complex world of CA 19-9 antibodies continues to grow, so too does the hope for improved cancer management and ultimately, a cure.
